Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB08937_nanopub.RAtHEF4TlVek0mDdaowqxz6MqrrElQxC_kE_o0VjsZ5ow#assertion>. }
Showing items 1 to 13 of
13
with 100 items per page.
- drugbank:DB08937 type drugbank_vocabulary:Drug assertion.
- drugbank:DB08937 label "TAS-102 [drugbank:DB08937]" assertion.
- drugbank:DB08937 seeAlso DB08937 assertion.
- drugbank:DB08937 description "TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer. It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine. Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trifluridine from being broken down when taken orally." assertion.
- drugbank:DB08937 identifier "drugbank:DB08937" assertion.
- drugbank:DB08937 title "TAS-102" assertion.
- drugbank:DB08937 drugbank_vocabulary:x-cas cas:733030-01-8 assertion.
- drugbank:DB08937 drugbank_vocabulary:drugbank-id "DB08937" assertion.
- drugbank:DB08937 bio2rdf_vocabulary:x-identifiers.org DB08937 assertion.
- drugbank:DB08937 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB08937" assertion.
- drugbank:DB08937 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB08937 bio2rdf_vocabulary:identifier "DB08937" assertion.
- drugbank:DB08937 drugbank_vocabulary:x-wikipedia wikipedia:TAS-102 assertion.